Interaction between smoking and CYP2C19*3 polymorphism increased risk of lung cancer in a Chinese population

Tumor Biology

Volumn 35, Issue 6, 2014, Pages 5295-5298

  Yan, Fei ^a   Xu, Jin Fu ^b   Liu, Xiao Fang ^c   Li, Xing Hua ^a  

^a SHANGHAI EIGHTH PEOPLE'S HOSPITAL   (China)

^b SHANGHAI PULMONARY HOSPITAL   (China)

^c SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Cytochrome P450; Epoxyeicosatrienoic acids; Lung cancer; Polymorphism; Smoking

Indexed keywords

CYTOCHROME P450 2C19;

ADULT; ARTICLE; CASE CONTROL STUDY; CHINESE; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; POPULATION MODEL; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SMOKING;

ADULT; AGED; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; FEMALE; GENOTYPE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RISK; SMOKING;

EID: 84904768602     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-1689-3     Document Type: Article

References (15)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
2. Zhang H, Cai B. The impact of tobacco on lung health in China. Respirology. 2003;8:17-21. (Pubitemid 36504276)
3. Liu X, Lin XJ, Wang CP, et al. Association between smoking and p53 mutation in lung cancer: a meta-analysis. Clin Oncol (R Coll Radiol). 2014;26:18-24.
4. Winkler V, Ott JJ, Cowan M, Becher H. Smoking prevalence and its impacts on lung cancer mortality in sub-Saharan Africa: an epidemiological study. Prev Med. 2013;57:634-40.
5. Tsou JA, Hagen JA, Carpenter CL, Laird-Offringa IA. DNA methylation analysis: a powerful new tool for lung cancer diagnosis. Oncogene. 2002;21:5450-61. (Pubitemid 34983481)
6. Yamamoto N, Murakami H, Hayashi H, et al. CYP2C19 genotype-based phase I studies of a c-Met inhibitor tivantinib in combination with erlotinib, in advanced/metastatic non-small cell lung cancer. Br J Cancer. 2013;109:2803-9.
7. Gan CQ, Wang XY, Cao YD, et al. Association of CYP2C19*3 gene polymorphismwith breast cancer in Chinesewomen. Genet Mol Res. 2011;10:3514-9.
8. Lim JS, Chen XA, Singh O, et al. Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients. Br J Clin Pharmacol. 2011;71:737-50.
9. Isomura Y, Yamaji Y, Ohta M, et al. A genetic polymorphism of CYP2C19 is associated with susceptibility to biliary tract cancer. J Gastroenterol. 2010;45:1045-52.
10. Xie X, Ma YT, Yang YN, et al. Personalized antiplatelet therapy according to CYP2C19 genotype after percutaneous coronary intervention: a randomized control trial. Int J Cardiol. 2013;168:3736-40.
11. Xie X, Ma YT, Yang YN, et al. CYP2C19 phenotype, stent thrombosis, myocardial infarction, and mortality in patients with coronary stent placement in a Chinese population. PLoS One. 2013;8:e59344.
12. Yang YN, Wang XL, Ma YT, et al. Association of interaction between smoking and CYP 2C19*3 polymorphism with coronary artery disease in a Uighur population. Clin Appl Thromb Hemost. 2010;16:579-83.
13. De Morais SM, Wilkinson GR, Blaisdell J, et al. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol. 1994;46:594-8. (Pubitemid 24334747)
14. Xing DL, Song DK, Zhang LR. Polymorphism of CYP2C19 gene in patients with bladder cancer. Zhengzhou Da Xue Xue Bao. 2006;41:285-7.
15. Mochizuki J, Murakami S, Sanjo A, et al. Genetic polymorphisms of cytochrome P450 in patients with hepatitis C virus-associated hepatocellular carcinoma. J Gastroenterol Hepatol. 2005;20:1191 -7.